Imatinib
- Generic Name
- Imatinib
- Brand Names
- Gleevec, Glivec, Imatinib Teva, Imatinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31N7O
- CAS Number
- 152459-95-5
- Unique Ingredient Identifier
- BKJ8M8G5HI
- Background
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...
- Indication
Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 20
- Registration Number
- NCT00512902
- Locations
- 🇺🇸
UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, California, United States
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 547
- Registration Number
- NCT00481247
- Locations
- 🇺🇸
Molecular Md, Portland, Oregon, United States
🇹🇷Local Institution, Kayseri, Turkey
ALL Adult Consortium Trial: Adult ALL Trial
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 112
- Registration Number
- NCT00476190
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Boston, Boston, Massachusetts, United States
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
- First Posted Date
- 2007-05-10
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 846
- Registration Number
- NCT00471497
- Locations
- 🇺🇸
University of California at Los Angeles Dept. of Hematology Clinic, Los Angeles, California, United States
🇺🇸Kaiser Permanente - California Northern Kaiser Med, Vallejo, California, United States
🇺🇸Florida Cancer Specialists Dept. FloridaCancerSpecialists, Fort Myers, Florida, United States
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00451997
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen
- Conditions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2007-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00426179
- Locations
- 🇬🇧
Novartis Investigative site, Horsham, United Kingdom
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00424515
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00422825
Imatinib in Adult Patients With Metastatic Ocular Melanoma
- Conditions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 13
- Registration Number
- NCT00421317
- Locations
- 🇫🇷
Centre Georges-Francois Leclerc, Dijon, France
🇫🇷Centre Francois Baclesse, Caen, France
🇫🇷Centre Hospitalier Regional Universitaire, Lille, France
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00420043
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.